CTOs on the Move

Aldeyra Therapeutics, Inc

www.aldeyra.com

 
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.aldeyra.com
  • 15 New England Executive Park
    Burlington, MA USA 01803
  • Phone: 781.270.0630

Executives

Name Title Contact Details

Funding

Aldeyra Therapeutics, Inc raised $60M on 03/26/2019
Aldeyra Therapeutics, Inc raised $74.7M on 01/20/2021
Aldeyra Therapeutics, Inc raised $125M on 04/28/2021

Similar Companies

BioSeek

BioSeek is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ebioscience

Ebioscience is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

onramp 113

onramp 113 is a Dixon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precision NanoSystem

Precision NanoSystems Inc. (PNI) creates innovative solutions that empower researchers to harness powerful nanotechnology to transform our understanding and treatment of diseases.

Unipex Solutions